StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Eli Lilly (LLY) PT Lowered to $305 at BMO Capital
February 4, 2022 6:55 AM
BMO Capital analyst Evan David Seigerman lowered the price target on Eli Lilly (NYSE: LLY) to $305.00 (from $310.00) while ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
Eli Lilly (LLY) PT Lowered to $293 at Mizuho Securities
February 4, 2022 6:37 AM
CFRA Downgrades Eli Lilly (LLY) to Hold
February 3, 2022 12:55 PM
Eli Lilly (LLY) Shares Trade Lower Despite Earnings, Guidance Beat; Analyst 'Encouraged by Fundamentals and Pipeline'
February 3, 2022 9:06 AM
Eli Lilly's (LLY) Fundamentals and Pipeline are Encouraging, Continue to Support Positive View - BMO Capital Markets
February 3, 2022 7:22 AM
Eli Lilly's (LLY) Earnings Outlook Continues to Look Favorable VS Peers, Reiterate Overweight - Cantor Fitzgerald
February 3, 2022 7:13 AM
Form 8-K ELI LILLY & Co For: Feb 03
February 3, 2022 7:09 AM
Eli Lilly pushes back timeline for Alzheimer's drug application
February 3, 2022 6:35 AM
Eli Lilly & Co. (LLY) Tops Q4 EPS by 34c, Revenue Beats, Offers Guidance
February 3, 2022 6:26 AM
Lilly Reports Solid Fourth-Quarter and Full-Year 2021 Financial Results, Recent Late-Stage Pipeline Successes Set Up Next Wave of Innovative Medicines for Patients
February 3, 2022 6:25 AM
